Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 24, 2015 10:07 PM ET


Company Overview of Novartis Pharma AG

Company Overview

Novartis Pharma AG provides treatments for Alzheimer’s disease, Parkinson’s disease, Attention-Deficit/Hyperactivity Disorder, epilepsy, schizophrenia, and migraine. It is also developing a treatment for type 2 diabetes; drugs therapies that improve insulin action to increase glucose disposal in the muscle, to limit its production in the liver, and to improve the kinetics of insulin secretion; and oral and physiological approach to enhancing glucagon like peptide-1 activity, which acts to stimulate insulin secretion and inhibit glucagon production. The company is based in Basel, Switzerland. Novartis Pharma AG operates as a subsidiary of Novartis AG.

Lichtstrasse 35

Basel,  4002



41 61 324 11 11


41 61 324 80 01

Key Executives for Novartis Pharma AG

President of HBA Europe and Head of New Marketing Initiatives
Compensation as of Fiscal Year 2015.

Novartis Pharma AG Key Developments

Novartis Pharma AG Presents at BIO-Europe 2015, Nov-02-2015 through Nov-04-2015

Novartis Pharma AG Presents at BIO-Europe 2015, Nov-02-2015 through Nov-04-2015. Venue: Munich, Germany. Presentation Date & Speakers: Nov-02-2015, Corinne Savill, Head, Pharma Business Development & Licensing.

Novartis Pharma AG Presents at 15th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-29-2015

Novartis Pharma AG Presents at 15th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-29-2015 . Venue: Congress Center, Basel, Switzerland. Speakers: Dimitrios Lizos, Innovation & External Relations Head.

CorTechs Labs and Novartis Pharma AG Announce Partnership to Provide Comprehensive Solutions for Quantifying Brain Volume Loss in Multiple Sclerosis

CorTechs Labs announced a partnership agreement with Novartis Pharma AG. The companies will collaborate to develop NeuroQuant's powerful brain volume quantification report targeting the identification, measurement and tracking of brain volume loss in multiple sclerosis patients. The resulting report enables clinicians to automatically conduct accurate and consistent measurements of the whole brain, left and right thalami and the lateral ventricles out of 3D T1 MRI images. The report is targeting the identification and tracking of neurodegeneration in these sub-cortical structures. This breakthrough solution, which is available both online and as an installed software solution, provides neurologists and radiologists with objective support of brain volume loss and its changes over time and as compared to normative values.

Similar Private Companies By Industry

Company Name Region
Robapharm Sa Europe
Lipomed AG Europe
ErgoNex Pharma GmbH Europe
Dompé International SA Europe
Janssen-Cilag AG Europe

Recent Private Companies Transactions

August 21, 2015
GlaxoSmithKline plc, Remaining Rights to Ofatumumab
January 23, 2015
Novartis Pharma AG, Worldwide Rights to encorafenib (LGX-818)

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Novartis Pharma AG, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at